JVRS 100

Drug Profile

JVRS 100

Alternative Names: JVRS-100

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Juvaris BioTherapeutics
  • Developer Penn State Milton S. Hershey Medical Center
  • Class Adjuvants; Antineoplastics; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Leukaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Leukaemia in USA (IV, Infusion)
  • 10 Sep 2011 JVRS 100 licensed to Colby Pharmaceutical Company worldwide
  • 05 Oct 2010 Pharmacodynamics data from preclinical trials released by Juvaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top